Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 433-436

  Kopreski, Michael S ^a,b   Lipton, Allan ^a   Harvey, Harold A ^a   Kumar, Rakesh ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Interferons; Monoclonal antibody; Tumor necrosis factor

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERFERON-ALPHA; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029919307     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, and Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Seshadri R, Firgaira FA, Horsfall DJ. McCaul K, Setlur V, and Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-1942, 1993.
4. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, and Senn H-J: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992.
5. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172, 1989.
6. Kumar R, Shepard HM, and Mendelsohn J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 11: 979-986, 1991.
7. Seliger B, Kruppa G, Schafer R, Redmond SMS, and Pfizenmaier K: Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription. J Virol 62: 619-621, 1988.
8. Giacomini P, Gambari R, Barbieri R, Nastruzzi C, Fraioli R, Spandidos D, Fisher PB, and Natali PG: Recombinant immune interferon down-regulates Ha-ras-1 proto-oncogene products in a human melanoma cell line. Anticancer Res 10: 629-635, 1990.
9. Marth C, Muller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE, and Daxenbichler G: γ-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50: 7037-7041. 1990.
10. Kumar R, and Mendelsohn J: Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-γ and tumor necrosis factor-α. Anticancer Res 14. 1001-1008. 1994.
11. Edmondson JM, Armstrong LS, and Martinez AO. A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures. J Tissue Culture Methods 11:15-17, 1988.
12. Russell SM, Krauer KG, McKenzie IFC, and Pietersz GA: Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. Cancer Res 50. 6028-6033, 1990.
13. Chiron M, Jaffrezou JP, Carayon P, Bordier C, Roubinet F, Xavier C, Brandely M, and Laurent G: Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity. Clin Exp Immunol 82: 214-220, 1990.
14. Greiner JW, Smalley RV, Borden EC. Martin EW, Guadagni F, Roselli M, and Schlom J: Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas. J Surg Oncol (Suppl.) 2: 9-13, 1991.
15. 131I-CC49) when given in combination with γ-interferon. Cancer Res 53:600-608, 1993
16. Kuhn JA, Wong JYC. Beatty BG, Esteban JM. Williams LE, and Beatty JD: γ-interferon enhancement of carcinoembryonic antigen expression in human colon carcinoma xenografts. J Immunother 11: 257-266, 1992.
17. Nakamura K, Kubo A, Hosokawa S, Nagaike K, and Hashimoto S: Effect of alpha-interferon on anti-alpha-fetoprotein-monoclonal antibody targeting of hepatoma. Oncol 50: 35-40. 1993.
18. Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, and Murray JL: Tumor necrosis factor α and γ-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells. J Immunother 13. 166-174, 1993.
19. Gridley DS, Slater JM, and Stickney DR: Effects of monoclonal antibody, recombinant interferon-γ, and tumor necrosis factor-α in the treatment of human melanoma xenografts. J Biol Response Mod 8: 593-602, 1989.
20. Eisenthal A, Cameron RB. and Rosenberg SA: Induction of antibody dependent cellular cytotoxicity in vivo by IFN-α and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 144: 4463-4471, 1990.
21. Van Dijk J, Uemura H, Beniers AJMC, Peelen WP, Zegveld ST, Fleuren GJ, Warnaar SO. and Oosterwijk E: Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 56: 262-268, 1994.
22. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, and Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994.
23. Zoon KC, Karasaki Y, zur Nedden DL, Hu R, and Arnheiter H. Modulation of epidermal growth factor receptors by human α interferon. Proc Natl Acad Sci USA 83. 8226-8230. 1986.
24. Lin SL, Kikuchi T, Pledger WJ, and Tamm I: Interferon inhibits the establishment of competence in Go/S-phase transition. Science 233: 356-359, 1986.
25. Schutze S, Machleidt T, and Kronke M: Mechanisms of tumor necrosis factor action. Semin Oncol 19 (Suppl. 4): 16-24, 1992.
26. Yamauchi N, Kuriyama H, Watanabe N, Neda H, Maeda M, and Niitsu Y: Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res 49: 1671-1675, 1989.
27. Schmid DS, Hornung R, McGrath KM, Paul N, and Ruddle NH. Target cell DNA fragmentation is mediated by lymphotoxin and tumor necrosis factor. Lymphokine Res 6: 195-202, 1987.
28. Fong C-J, Sherwood ER, Mendelsohn J, Lee C, and Kozlowski JM: Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α. Cancer Res 52: 5887-5892, 1992.